1. Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children’s Oncology Group Study A5962 
Richard E. Harris, Amanda M. Termuhlen, Lynette M. Smith, James Lynch, Michael M. Henry, Sherrie L. Perkins, Thomas G. Gross, Phyllis Warkentin, Adrianna Vlachos, Lauren Harrison, Mitchell S. Cairo 
Biology of Blood and Marrow Transplantation 
Volume 17, Issue 2, Pages (February 2011)
DOI: /j.bbmt
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Flow diagram of patients from diagnosis and study entry, following reinduction, autologous PBSCT, and final outome.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) OS of all patients from date of relapse or progressive disease calculated by the method of Kaplan-Meier. (B) Comparison of OS from time of relapse or progressive disease in HL versus NHL patients calculated by the method of Kaplan-Meier.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) EFS of all patients from date of relapse or progressive disease calculated by the method of Kaplan-Meier. (B) Comparison of EFS from time of relapse or progressive disease in HL versus NHL patients calculated by the method of Kaplan-Meier.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
(A) Comparison of OS from date of relapse or progressive disease in patients achieving a CR/PR versus SD/PD following reinduction calculated by the method of Kaplan-Meier. All patients were included except those who were inevaluable for response because of early toxic or infectious death (n = 5). (B) Comparison of EFS from date of relapse or progressive disease in patients achieving a CR/PR versus SD/PD following reinduction calculated by the method of Kaplan-Meier. All patients were included except those who were inevaluable for response because of early toxic or infectious death (n = 5).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 5
Comparison of OS from date on study (all patients) in patients with first remission <12 months versus patients with first remission ≥12 months calculated by the method of Kaplan-Meier.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2011 American Society for Blood and Marrow Transplantation Terms and Conditions